Traumatic Brain Injury - Pipeline Review, H1 2015

Publisher Name :
Date: 31-Mar-2015
No. of pages: 265
Inquire Before Buying

Global Markets Direct’s, ‘Traumatic Brain Injury - Pipeline Review, H1 2015’, provides an overview of the Traumatic Brain Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Traumatic Brain Injury and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Traumatic Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products


Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Traumatic Brain Injury - Pipeline Review, H1 2015

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Traumatic Brain Injury Overview 10
Therapeutics Development 11
Pipeline Products for Traumatic Brain Injury - Overview 11
Pipeline Products for Traumatic Brain Injury - Comparative Analysis 12
Traumatic Brain Injury - Therapeutics under Development by Companies 13
Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes 18
Traumatic Brain Injury - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Traumatic Brain Injury - Products under Development by Companies 23
Traumatic Brain Injury - Products under Investigation by Universities/Institutes 28
Traumatic Brain Injury - Companies Involved in Therapeutics Development 29
Adamas Pharmaceuticals, Inc. 29
ALSP, Inc. 30
Amarantus Bioscience Holdings, Inc. 31
Athersys, Inc. 32
BHR Pharma, LLC 33
Cognosci, Inc. 34
Concert Pharmaceuticals, Inc. 35
Euroscreen S.A. 36
Grupo Ferrer Internacional, S.A. 37
International Stem Cell Corporation 38
Io Therapeutics, Inc. 39
Ischemix 40
Karyopharm Therapeutics, Inc. 41
Kyorin Pharmaceutical Co., Ltd. 42
Levolta Pharmaceuticals, Inc. 43
Lixte Biotechnology Holdings, Inc. 44
Lpath, Inc. 45
MandalMed, Inc. 46
Mapreg S.A.S. 47
Mnemosyne Pharmaceuticals, Inc. 48
NeoStem, Inc. 49
Neuralstem, Inc. 50
Neuren Pharmaceuticals Limited 51
NeuroHealing Pharmaceuticals Inc. 52
NeuroNascent, Inc. 53
Neuronax SAS 54
NeuroVive Pharmaceutical AB 55
Omeros Corporation 56
PharmatrophiX, Inc. 57
Phylogica Limited 58
Prevacus, Inc. 59
PsychoGenics, Inc. 60
QR Pharma, Inc. 61
RAPID Pharmaceuticals AG 62
RegeneRx Biopharmaceuticals, Inc. 63
Remedy Pharmaceuticals, Inc. 64
Sage Therapeutics 65
SanBio, Inc. 66
STATegics, Inc. 67
SynZyme Technologies, LLC 68
Tetra Discovery Partners LLC 69
vasopharm GmbH 70
VG Life Sciences, Inc. 71
Traumatic Brain Injury - Therapeutics Assessment 72
Assessment by Monotherapy Products 72
Assessment by Combination Products 73
Assessment by Target 74
Assessment by Mechanism of Action 77
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 84
2-DG - Drug Profile 84
ALP-496 - Drug Profile 86
amantadine hydrochloride ER - Drug Profile 88
AMR-001 - Drug Profile 90
AMRS-001 - Drug Profile 92
apomorphine hydrochloride - Drug Profile 94
AVL-8168 - Drug Profile 96
BHR-310 - Drug Profile 97
C-10068 - Drug Profile 98
Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 99
CHEC-7 - Drug Profile 100
CHEC-9 - Drug Profile 101
CMX-2043 - Drug Profile 103
CNB-001 - Drug Profile 105
COG-1410 - Drug Profile 107
cyclosporine - Drug Profile 109
dexamethasone acetate + melatonin - Drug Profile 112
EPO-Variant - Drug Profile 113
ESN-502 - Drug Profile 114
felbamate - Drug Profile 115
FIB-117 - Drug Profile 116
glyburide - Drug Profile 117
HBN-1 - Drug Profile 119
HBN-2 - Drug Profile 120
ibudilast - Drug Profile 121
ICCN-100 - Drug Profile 123
IRX-4204 - Drug Profile 124
KPT-350 - Drug Profile 126
LB-201 - Drug Profile 127
LB-205 - Drug Profile 128
LM11A-31 - Drug Profile 129
Lpathomab - Drug Profile 130
MAP-4343 - Drug Profile 131
MultiStem - Drug Profile 132
ND-478 - Drug Profile 135
NNI-370 - Drug Profile 136
NNZ-2591 - Drug Profile 137
NSI-189 - Drug Profile 139
NSI-566 - Drug Profile 140
NVP-019 - Drug Profile 142
NVX-428 - Drug Profile 143
NX-210 - Drug Profile 144
Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile 145
PGI-02776 - Drug Profile 146
Posiphen - Drug Profile 148
progesterone - Drug Profile 150
PRV-002 - Drug Profile 151
PYC-35 - Drug Profile 152
PYC-36 - Drug Profile 153
PYC-38 - Drug Profile 154
PYC-98 - Drug Profile 155
R-503 - Drug Profile 156
RAP-701 - Drug Profile 158
RGN-352 - Drug Profile 159
SAGE-547 - Drug Profile 161
SB-623 - Drug Profile 163
Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 164
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 165
Small Molecule to Antagonize NMDA2A for Central Nervous System Disorder - Drug Profile 166
Small Molecule to Inhibit Amyloid Beta Peptide for Traumatic Brain Injury and Alzheimer’s Disease - Drug Profile 167
Small Molecule to Inhibit PDE4 for Traumatic Brain Injury - Drug Profile 168
Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile 169
Small Molecules to Activate P2Y Receptor for Stroke and Traumatic Brain Injury - Drug Profile 170
Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile 171
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 172
Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile 173
Stem Cell Therapy for Parkinson’s Disease, Traumatic Brain Injury and Stroke - Drug Profile 174
Stem Cell Therapy for Traumatic Spinal Cord Injury and Brain Injury - Drug Profile 176
STSE-15 - Drug Profile 177
TBI-121 - Drug Profile 178
TBI-122 - Drug Profile 179
TBI-123 - Drug Profile 180
trofinetide - Drug Profile 181
UH-0113 - Drug Profile 183
UH-0213 - Drug Profile 184
VAS-203 - Drug Profile 185
VG-1177 - Drug Profile 187
VitalHeme - Drug Profile 189
VOLT-02 - Drug Profile 191
Traumatic Brain Injury - Recent Pipeline Updates 192
Traumatic Brain Injury - Dormant Projects 245
Traumatic Brain Injury - Discontinued Products 249
Traumatic Brain Injury - Product Development Milestones 250
Featured News & Press Releases 250
Appendix 258
Methodology 258
Coverage 258
Secondary Research 258
Primary Research 258
Expert Panel Validation 258
Contact Us 258
Disclaimer 259

List of Tables

Number of Products under Development for Traumatic Brain Injury, H1 2015 17
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 20
Number of Products under Development by Companies, H1 2015 (Contd..1) 21
Number of Products under Development by Companies, H1 2015 (Contd..2) 22
Number of Products under Development by Companies, H1 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2015 24
Comparative Analysis by Late Stage Development, H1 2015 25
Comparative Analysis by Clinical Stage Development, H1 2015 26
Comparative Analysis by Early Stage Development, H1 2015 27
Comparative Analysis by Unknown Stage Development, H1 2015 28
Products under Development by Companies, H1 2015 29
Products under Development by Companies, H1 2015 (Contd..1) 30
Products under Development by Companies, H1 2015 (Contd..2) 31
Products under Development by Companies, H1 2015 (Contd..3) 32
Products under Development by Companies, H1 2015 (Contd..4) 33
Products under Investigation by Universities/Institutes, H1 2015 34
Traumatic Brain Injury - Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 35
Traumatic Brain Injury - Pipeline by ALSP, Inc., H1 2015 36
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 37
Traumatic Brain Injury - Pipeline by Athersys, Inc., H1 2015 38
Traumatic Brain Injury - Pipeline by BHR Pharma, LLC, H1 2015 39
Traumatic Brain Injury - Pipeline by Cognosci, Inc., H1 2015 40
Traumatic Brain Injury - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 41
Traumatic Brain Injury - Pipeline by Euroscreen S.A., H1 2015 42
Traumatic Brain Injury - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 43
Traumatic Brain Injury - Pipeline by International Stem Cell Corporation, H1 2015 44
Traumatic Brain Injury - Pipeline by Io Therapeutics, Inc., H1 2015 45
Traumatic Brain Injury - Pipeline by Ischemix, H1 2015 46
Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 47
Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 48
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals, Inc., H1 2015 49
Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 50
Traumatic Brain Injury - Pipeline by Lpath, Inc., H1 2015 51
Traumatic Brain Injury - Pipeline by MandalMed, Inc., H1 2015 52
Traumatic Brain Injury - Pipeline by Mapreg S.A.S., H1 2015 53
Traumatic Brain Injury - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 54
Traumatic Brain Injury - Pipeline by NeoStem, Inc., H1 2015 55
Traumatic Brain Injury - Pipeline by Neuralstem, Inc., H1 2015 56
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Limited, H1 2015 57
Traumatic Brain Injury - Pipeline by NeuroHealing Pharmaceuticals Inc., H1 2015 58
Traumatic Brain Injury - Pipeline by NeuroNascent, Inc., H1 2015 59
Traumatic Brain Injury - Pipeline by Neuronax SAS, H1 2015 60
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2015 61
Traumatic Brain Injury - Pipeline by Omeros Corporation, H1 2015 62
Traumatic Brain Injury - Pipeline by PharmatrophiX, Inc., H1 2015 63
Traumatic Brain Injury - Pipeline by Phylogica Limited, H1 2015 64
Traumatic Brain Injury - Pipeline by Prevacus, Inc., H1 2015 65
Traumatic Brain Injury - Pipeline by PsychoGenics, Inc., H1 2015 66
Traumatic Brain Injury - Pipeline by QR Pharma, Inc., H1 2015 67
Traumatic Brain Injury - Pipeline by RAPID Pharmaceuticals AG, H1 2015 68
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 69
Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 70
Traumatic Brain Injury - Pipeline by Sage Therapeutics, H1 2015 71
Traumatic Brain Injury - Pipeline by SanBio, Inc., H1 2015 72
Traumatic Brain Injury - Pipeline by STATegics, Inc., H1 2015 73
Traumatic Brain Injury - Pipeline by SynZyme Technologies, LLC, H1 2015 74
Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1 2015 75
Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1 2015 76
Traumatic Brain Injury - Pipeline by VG Life Sciences, Inc., H1 2015 77
Assessment by Monotherapy Products, H1 2015 78
Assessment by Combination Products, H1 2015 79
Number of Products by Stage and Target, H1 2015 81
Number of Products by Stage and Mechanism of Action, H1 2015 84
Number of Products by Stage and Route of Administration, H1 2015 87
Number of Products by Stage and Molecule Type, H1 2015 89
Traumatic Brain Injury Therapeutics - Recent Pipeline Updates, H1 2015 198
Traumatic Brain Injury - Dormant Projects, H1 2015 251
Traumatic Brain Injury - Dormant Projects (Contd..1), H1 2015 252
Traumatic Brain Injury - Dormant Projects (Contd..2), H1 2015 253
Traumatic Brain Injury - Dormant Projects (Contd..3), H1 2015 254
Traumatic Brain Injury - Discontinued Products, H1 2015 255

List of Figures

Number of Products under Development for Traumatic Brain Injury, H1 2015 17
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 19
Number of Products under Investigation by Universities/Institutes, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 26
Comparative Analysis by Early Stage Products, H1 2015 27
Assessment by Monotherapy Products, H1 2015 78
Number of Products by Top 10 Targets, H1 2015 80
Number of Products by Stage and Top 10 Targets, H1 2015 80
Number of Products by Top 10 Mechanism of Actions, H1 2015 83
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 83
Number of Products by Top 10 Routes of Administration, H1 2015 86
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 87
Number of Products by Top 10 Molecule Types, H1 2015 88
Number of Products by Stage and Top 10 Molecule Types, H1 2015 89

  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Global Hypercalcemia Treatment Market 2017-2021
    Published: 19-Apr-2017        Price: US 3500 Onwards        Pages: 70
    ABSTRACT About Hypercalcemia Treatment Hypercalcemia is a condition in which the calcium level in the blood is above normal. Too much calcium in the blood can weaken the bones, create stones in the kidneys, and interfere with the functioning of the heart and the brain. Hypercalcemia refers to the condition where too much calcium enters the extracellular fluid or when there is insufficient calcium excretion from the kidneys. The cases of hypercalcemia are mainly caused by ma......
  • Friedreich Ataxia - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 85
    Friedreich Ataxia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape. Friedreich's ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed dow......
  • Liver Fibrosis - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 200
    Liver Fibrosis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Fibrosis - Pipeline Review, H1 2017, provides an overview of the Liver Fibrosis (Gastrointestinal) pipeline landscape. Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the l......
  • Fragile X Syndrome - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 108
    Fragile X Syndrome - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape. Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, re......
  • Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021
    Published: 05-Apr-2017        Price: US 3500 Onwards        Pages: 70
    HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to variou......
  • Sarcopenia - Epidemiology Forecast To 2023
    Published: 01-Apr-2017        Price: US 2750 Onwards        Pages: 51
    DelveInsight's "Sarcopenia - Epidemiology Forecast To 2023" Report provides an overview of the epidemiology trends of Sarcopenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023. Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after......
  • Natural Killer Cells Therapies- Competitive Landscape,Technology and Pipeline Analysis, 2017
    Published: 01-Apr-2017        Price: US 2450 Onwards        Pages: 207
    DelveInsight's report, "Natural Killer Cells Therapies- Competitive Landscape, Technology and Pipeline Analysis, 2017", emphasizes on the currently active NK cell therapy products and NK cell augmenters in research and development. The report covers 20+ companies, which are active in this field with 40+ products and many different technologies. This report covers NK cell based therapies and drugs that augment (enhance or activate) the NK cells. The report provides in-depth analysis on t......
  • Sarcopenia - Market Insights, Epidemiology and Market Forecast -2023-7 MM
    Published: 01-Apr-2017        Price: US 4950 Onwards        Pages: 51
    DelveInsight's "Sarcopenia - Market Insights, Epidemiology and Market Forecast-2023-7 MM" Report provides an overview of the disease and global market size of the Sarcopenia for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023. Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most peopl......
  • Acromegaly and Gigantism- Epidemiology Forecast To 2023
    Published: 01-Apr-2017        Price: US 2750 Onwards        Pages: 51
    DelveInsight's"Acromegaly and Gigantism- Epidemiology Forecast to 2023" Report provides an overview of the epidemiology trends of Acromegaly in seven major markets (US, France, Germany, Italy, Spain, UK and Japan) and Gigantism in six major markets (US, United Kingdom, France, Germany, Italy and Spain). It includes 10 years epidemiology historical and forecasted data of prevalent cases of Acromegaly and Gigantism by age, sex and sub populations. The Report also discusses the prevailing risk fact......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs